Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Wiemers

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
NPJ Digital Medicine|May 11, 2026
Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligenceMaximilian Ferle, Jonas Ader, Thomas Wiemers, et al.
Transplantation and Cellular Therapy|May 17, 2026
Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple MyelomaNora Grieb, Thomas Wiemers, Patrick Born, et al.
Blood Cancer Discovery|October 23, 2024
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaDavid Fandrei, Sabine Seiffert, Michael Rade, et al.
Cancer Cell|December 5, 2025
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaMichael Rade, David Fandrei, Markus Kreuz, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
NPJ Digital Medicine|May 11, 2026
Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligenceMaximilian Ferle, Jonas Ader, Thomas Wiemers, et al.
Transplantation and Cellular Therapy|May 17, 2026
Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple MyelomaNora Grieb, Thomas Wiemers, Patrick Born, et al.
Blood Cancer Discovery|October 23, 2024
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaDavid Fandrei, Sabine Seiffert, Michael Rade, et al.
Cancer Cell|December 5, 2025
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaMichael Rade, David Fandrei, Markus Kreuz, et al.
Pageof 1